Abstract
Abstract Immunotherapies have been proposed as a therapeutic strategy for the treatment of Parkinson disease (PD). Intravenous immunoglobulin preparation (IVIg) is used for the treatment of immunodeficiency and autoimmune diseases. Here, we investigated the effect of IVIg treatment on the dopaminergic (DAergic) nigrostriatal system after MPTP-induced denervation in mice. Mice received 4 MPTP injections (15 mg/Kg) at 2-hour intervals followed by a 14 days treatment with IVIg. IVIg injections led to a 21,6% increase in TReg cells in vehicle group (p<0.05) and minimal specific immune response. As expected, MPTP insult induced a significant 80% and 84% depletion of striatal dopamine content (p<0.01), as well as a 31% and 45% nigral DAergic neuron loss (p<0.001) in the Control and IVIg group, respectively. Moreover, two-way ANOVA analyses revealed a significant downregulating effect of IVIg on striatal tyrosine hydroxylase protein level (-16%, p<0.05) and on the number of nigral DAergic neurons (-29%, p<0.05), paralleling the toxic effect of MPTP. Collectively, our results provide no evidence of a neurorestorative effect of IVIg on the nigrostriatal system of the MPTP-treated mouse, and suggest that we need to proceed with caution before treating PD patients with IVIg.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
